Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin and Alemtuzumab for Allogeneic HSCT in High-Risk Malignancies
NCT00698685Phase 2Terminated
- Sponsor
- University of Arizona
- Start
- Jan 2006
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of pentostatin, alemtuzumab in leukemia, lymphoma, Hodgkin lymphoma (HL), hematologic neoplasm, multiple myeloma (MM), sponsored by University of Arizona. Started Jan 2006; status: terminated.
02
Drugs
pentostatinalemtuzumab
03
Conditions
leukemialymphomaHodgkin lymphoma (HL)hematologic neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT00698685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698685.